Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study.
Kamlesh Khunti F MedSciBernard CharbonnelAndrew CooperMarília Brito GomesLi-Nong JiPaul LeighAntonio NicolucciWolfgang RathmannMarina V ShestakovaAfrah SiddiquiFengming TangHirotaka WatadaHungta Chennull nullPublished in: Diabetes, obesity & metabolism (2021)
Combinations of metformin with an SU were associated with the lowest weight reduction, highest risk of hypoglycaemia and lower SF-36v2 scores.